Processa Pharmaceuticals, Inc. (PCSA) – 2023 Annual Report Summary

Processa Pharmaceuticals is a clinical-stage company developing innovative therapies for cancer and rare diseases. Its core strategy, "Next Generation Cancer therapy" (NGC), aims to improve the effectiveness and reduce the side effects of existing cancer drugs. The company also develops treatments for underserved rare conditions like Necrobiosis Lipoidica (NL).

As of March 15, 2024, Processa Pharmaceuticals was a micro-cap biotechnology firm with a market capitalization of approximately $8.1 million and roughly 2.66 million shares outstanding.

1. Business Overview Processa Pharmaceuticals actively advances a pipeline of drug candidates. These include PCS6422 for metastatic colorectal cancer (mCRC) and other solid tumors, and PCS499 for Necrobiosis Lipoidica (NL). The company's unique NGC approach optimizes the metabolism of existing chemotherapy agents to enhance efficacy and reduce toxicity. For NL, PCS499 offers a potential first-in-class oral treatment for a condition with no approved therapies.

The company also explores digital assets, such as cryptocurrencies and stablecoins, as a way to fund its drug development programs without issuing more stock. This strategy aims to use potential gains from digital asset investments to offset research and development (R&D) costs, though it introduces new financial risks.

2. Financial Performance (Fiscal Year Ended December 31, 2023) As a clinical-stage biotechnology company, Processa Pharmaceuticals reported no significant product revenue for fiscal year 2023.

• Revenue: $0.1 million (primarily from grants or minor collaborations), consistent with the prior year.
• Net Loss: The company reported a net loss of approximately $25.5 million for 2023, an increase from $22.0 million in 2022. This larger loss reflects substantial investment in research and development activities.
• Research & Development (R&D) Expenses: R&D expenses rose to $18.7 million in 2023 from $16.5 million in 2022, driven by increased clinical trial activities for PCS6422 and PCS499.
• General & Administrative (G&A) Expenses: G&A expenses were $6.8 million in 2023, compared to $5.5 million in 2022. This increase was partly due to higher legal and professional fees associated with public company operations and the implementation of its digital asset strategy.

3. Risk Factors Investors should understand several significant risks inherent in Processa Pharmaceuticals' business:

• Funding Challenges: The company requires substantial additional financing to complete clinical trials and commercialize products. Inadequate funding could delay or halt development programs.
• Digital Asset Volatility: The value of the company's digital asset holdings faces extreme market volatility, regulatory changes, and cybersecurity risks. These factors could negatively impact its financial position and ability to fund operations.
• Clinical Trial Success & Timelines: Drug development is inherently risky. PCS6422 or PCS499 may not achieve positive results in ongoing or future clinical trials, or trials may exceed anticipated timelines or budgets.
• Regulatory Approvals: Obtaining and maintaining FDA and other regulatory approvals is a lengthy, complex, and uncertain process. Delays or failures could significantly impact the company's prospects.
• Market Acceptance: Even if approved, the company's products may not achieve market acceptance among physicians, patients, and payers.
• Intellectual Property Protection: Success depends on protecting its proprietary technology and trade secrets.
• Competition: The pharmaceutical industry is highly competitive; larger, more established companies possess greater resources.
• Reliance on Third Parties: Processa relies heavily on Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) for clinical development and manufacturing. If these partners fail to perform, operations could be disrupted.

4. Management's Discussion and Analysis (MD&A) Highlights Management's discussion of the company's financial condition and results of operations for 2023 highlighted significant progress in its clinical pipeline alongside increased operating expenses.

• Key Achievements:
  • PCS6422 (mCRC): Completed patient enrollment for the Phase 2b trial in mCRC, with initial data expected in Q3 2024.
  • PCS499 (NL): Started a pivotal Phase 2b/3 trial for NL, dosing the first patient in Q4 2023.
  • Digital Asset Strategy: Established initial digital asset infrastructure and made preliminary investments to generate non-dilutive capital.
• Challenges:
  • Funding: Relies on volatile capital markets and its nascent digital asset strategy for funding.
  • Clinical Trial Delays: Experienced minor patient recruitment delays for the PCS499 trial due to the rarity of the condition.
  • Increased Operating Costs: Higher R&D and G&A expenses led to a larger net loss, reflecting advanced clinical development.
• Leadership: Executive leadership remained consistent in 2023, indicating continuity in strategic direction.

5. Financial Health As of December 31, 2023, Processa Pharmaceuticals' financial position reflected its status as a clinical-stage company with substantial cash expenditures.

• Cash and Cash Equivalents: $12.3 million, down from $25.8 million at the end of 2022, primarily funding operating expenses.
• Working Capital Deficit: The company reported a $3.5 million working capital deficit, meaning current liabilities exceeded current assets.
• Debt: Minimal long-term debt, mainly lease obligations.
• Cash Usage: Processa used approximately $6.5 million in cash per quarter in 2023.
• Going Concern: The company's ability to continue operations depends on raising additional capital through equity offerings, strategic partnerships, or successfully executing its digital asset strategy. Management estimates current cash will fund operations into Q3 2024.

6. Future Outlook Processa Pharmaceuticals' future outlook focuses on advancing its clinical pipeline and securing necessary funding. The company reaffirmed its dual strategy: advancing core drug development programs and actively pursuing its digital asset funding model to support long-term growth and reduce reliance on traditional equity financing.

• Guidance & Milestones (2024-2025):
  • Q3 2024: Expects to release initial data from the PCS6422 Phase 2b trial in mCRC.
  • H2 2024: Continues patient enrollment and may release interim data from the PCS499 pivotal Phase 2b/3 trial for NL.
  • 2025: PCS6422 could advance to a pivotal Phase 3 trial, pending positive Phase 2b results and adequate funding.
• Funding Strategy: Securing additional capital through equity raises, strategic partnerships, and a maturing digital asset investment strategy is critical for achieving these milestones.

7. Competitive Position Processa differentiates itself through its Next Generation Cancer (NGC) approach, which improves existing, proven cancer therapies. This strategy could offer a faster path to market and reduced development risk compared to entirely novel compounds, by leveraging known mechanisms of action. For Necrobiosis Lipoidica (NL), PCS499 targets an orphan disease with no approved treatments, positioning it for significant market potential as a potential first-in-class therapy.

Key oncology competitors include large pharmaceutical companies with broad pipelines and substantial resources, and other biotechnology firms developing novel or improved cancer treatments. In rare diseases, competition can arise from other small biotechs developing targeted therapies or from existing drugs used off-label. Processa's success depends on demonstrating superior efficacy, safety, or convenience compared to current standards of care or emerging treatments.

Market Trends & Regulatory Environment The oncology market continues to grow, with increasing demand for targeted, less toxic therapies, aligning with Processa's NGC strategy. The rare disease market also remains attractive due to faster regulatory pathways and premium pricing potential. The rapidly evolving regulatory landscape for digital assets could impact the company's funding strategy, requiring close monitoring and adaptation.